Alnylam Pharmaceuticals, a RNAi therapeutics company, announced that the US Food and Drug Administration (FDA) has granted fast track designation to patisiran (ALN-TTR02) for the treatment of transthyretin (TTR)-familial amyloid ...
Tags: Alnylam, Fast Track Designation
RNAi therapeutics company Alnylam Pharmaceuticals has obtained additional orphan drug designation from US FDA for a RNAi therapeutic, ALN-AT3, to treat hemophilia A. With the additional approval, orphan drug designation for GalNAc ...
Tags: Alnylam, Orphan Drug
The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to Arrowhead Research's patent application NO.13/336,028 covering dynamic polyconjugate (DPC) siRNA delivery system. The patent entitled, 'In Vivo ...
Tags: Arrowhead, NOA, therapeutic area targets
Marina Biotech has won a patent in the US protecting unlocked nucleobase analog (UNA) modification and substitution chemistry. Patent broadly covers RNA-based oligonucleotide therapeutics such as a RNA duplex, a microRNA mimic, a microRNA ...
Tags: Marina Biotech, UNA, substitution chemistry
The US Patent and Trademark Office(USPTO)has granted a Notice of Allowance(NOA)to Silence Therapeutics for claims related to interfering RNA molecules and lipid complexes used in drug delivery. The NOA,which is issued based on the ...
Tags: Silence Therapeutics, RNAi therapeutics, Silence Company, RNA molecules